Utah Medical Products (UTMD) EBITDA (2010 - 2026)

Utah Medical Products has reported EBITDA for 17 years, with the latest figure at $2.6 million in Q2 2026.

• On a quarterly basis, EBITDA fell 17.12% year-over-year to $2.6 million in Q2 2026; TTM through Jun 2026 was $10.3 million, a 18.67% decrease from a year earlier, with the FY2025 full-year figure at $11.4 million, down 16.12% from the prior year.
• EBITDA was $2.6 million for Q2 2026 at Utah Medical Products, up from $2.6 million in the prior quarter.
• The five-year high for EBITDA was $5.1 million in Q3 2022, with the low at $2.4 million in Q4 2025.
• Average EBITDA over 5 years is $3.7 million, with a median of $3.7 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: EBITDA advanced 16.31% in 2022, then slipped 25.71% in 2024.
• Over 5 years, EBITDA stood at $5.1 million in 2022, then dropped by 22.21% to $3.9 million in 2023, then retreated by 25.71% to $2.9 million in 2024, then fell by 16.69% to $2.4 million in 2025, then climbed by 8.52% to $2.6 million in 2026.
• The last three EBITDA figures came in at $2.6 million (Q2 2026), $2.6 million (Q1 2026), and $2.4 million (Q4 2025), per Business Quant data.